Table 1 Clinical correlations of miR-125a expression in cervical carcinoma
From: MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression
Variables | miR-125a expression in tumor tissues (T) | P-value | |
|---|---|---|---|
High expression | Low expression | ||
N=22 (51.2%) | N=21 (48.8%) | ||
Age (mean±s.d.), years | 53.6±9.78 | 55.9±10.15 | 0.911 |
Tumor size | |||
 <4 cm | 10 (23.3%) | 3 (7.0%) | 0.045a |
 ⩾4 cm | 12 (27.9%) | 18 (41.9%) | |
SCC-Ag | |||
 <1.5 ng/ml | 13 (30.2%) | 10 (23.3%) | 0.547 |
 ⩾1.5 ng/ml | 9 (20.9%) | 11 (25.6%) | |
Histology | |||
 Adenocarcinoma | 2 (4.7%) | 3 (7.0%) | 0.664 |
 Squamous | 20 (46.5%) | 18 (41.9%) | |
FIGO stage | |||
I/II | 15 (34.9%) | 6 (14.0%) | 0.015a |
III/IV | 7 (16.3%) | 15 (34.9%) | |
Treat with paclitaxel | |||
 Response | 16 (37.2%) | 7 (16.3%) | 0.015a |
 No response | 6 (14.0%) | 14 (34.9%) | |
